Crossmark

Surufatinib — a novel oral agent for neuroendocrine tumours

Crossref DOI link: https://doi.org/10.1038/s41574-020-00439-0

Published Online: 2020-10-30

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Koumarianou, Anna

Kaltsas, Gregory https://orcid.org/0000-0002-5876-7883
License Information

Text and Data Mining valid from 2020-10-30

Version of Record valid from 2020-10-30
More Information

Article History

First Online: 30 October 2020

Competing interests

: The authors declare no competing interests.